Abstract
Superantigens have been implicated in a wide variety of human diseases. Yet, solid evidence for their role in pathogenesis is available only for Toxic Shock Syndrome and a few other conditions. This evidence is critically reviewed herein.
Similar content being viewed by others
REFERENCES
Bohach GA, Fast DJ, Nelson RD, Schlievert PM: Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17:251–272, 1990
Rott O, Fleischer B: A superantigen as virulence factor in an acute bacterial infection. J Infect Dis 169:1142–1146, 1994
Held W, Waanders GA, Shakhov AN, Scarpellino L, Acha-Orbea H, MacDonald HR: Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell 74:529–540, 1993
Ross SR: Mouse mammary tumor virus and its interaction with the immune system. Immunol Res 17:209–216, 1998
White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P: The Vb-specific superantigen staphylococcal enterotoxin B: Stimulation of mature T cells and clonal deletion in neonatal mice. Cell 57:27–35, 1989
Festenstein H: Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse. Transplant Rev 15:62–88, 1973
Langford MP, Stanton GJ, Johnson HM: Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes. Infect Immun 22:62–68, 1978
Proft T, Moffatt SL, Berkahn CJ, Fraser JD: Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 189:89–101, 1999
Mehindate K, Thibodeau J, Dohlsten M, Kalland T, Sekaly RP, Mourad W: Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med 182:1573–1577, 1995
Chatila T, Geha RS: Signal transduction by microbial superantigens via MHC class II molecules. Immunol Rev 131:43–60, 1993
Thibodeau J, Cloutier I, Lavoie PM, et al.: Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. Science 266:1874–1878, 1994
Yagi J, Nakata M, Uchiyama T, et al.: Superantigen-like properties of an antibody bispecific for MHC class II molecules and the V beta domain of the T cell antigen receptor. J Immunol 152:3833–3841, 1994
Ratcliffe MJ, Coggeshall KM, Newell MK, Julius MH: T cell receptor aggregation, but not dimerization, induces increased cytosolic calcium concentrations and reveals a lack of stable association between CD4 and the T cell receptor. J Immunol 148:1643–1651, 1992
Currier JR, Yassai M, Robinson MA, Gorski J: Molecular defects in TCRBV genes preclude thymic selection and limit the expressed TCR repertoire. J Immunol 157:170–175, 1996
Wei S, Charmley P, Robinson MA, Concannon P: The extent of the human germline T-cell receptor V beta gene segment repertoire. Immunogenetics 40:27–36, 1994
Levinson AI, Kozlowski LM: B-cell superantigens and their biological implications. In Superantigens: Molecular Biology, Immunology and Relevance to Human Disease, DYM Leung, BT Huber, PM Schlievert (eds). New York, Marcel Dekker, 1997, p 405
Zabriskie JB: The role of temperate bacteriophage in the production of erythrogenic toxin by group A streptococci. J Exp Med 119:761, 1964
Fleischer B, Necker A, Leget C, Malissen B, Romagne F: Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens. Infect Immun 64:987–994, 1996
Fleischer B, Bailey CJ: Recombinant epidermolytic (exfoliative) toxin A of Staphylococcus aureus is not a superantigen. Med Microbiol Immunol (Berl) 180:273–278, 1992
Fleischer B, Hartwig U: T lymphocyte stimulation by microbial superantigens. In Biological Significance of Superantigens, B Fleischer (ed). Basel, Karger, 1992, p 36
Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B: A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 90:303–313, 1997
Huang Z, Vafai A, Lee J, Mahalingam R, Hayward AR: Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. J Virol 66:2664–2669, 1992
Oxman MN: Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45:S41-S46, 1995
Nader S, Bergen R, Sharp M, Arvin AM: Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171:13–17, 1995
McCormack JE, Callahan JE, Kappler J, Marrack PC: Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol 150:3785–3792, 1993
Kotzin BL, Leung D, Kappler J, Marrack P: Superantigens and their potential role in human disease. Adv Immunol 54:99–166, 1993
Choi Y, Lafferty JA, Clements JR, et al.: Selective expansion of T cells expressing Vb2 in toxic shock syndrome. J Exp Med 172:981–984, 1990
Watanabe-Ohnishi R, Low DE, McGeer A, et al.: Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project [see comments]. J Infect Dis 171:74–84, 1995
Vella AT, McCormack JE, Linsley PS, Kappler JW, Marrack P: Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2:261–270, 1995
Vella AT, Mitchell T, Groth B, et al.: CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J Immunol 158:4714–4720, 1997
Biasi G, Panozzo M, Pertile P, Mezzalira S, Facchinetti A: Mechanism underlying superantigen-induced clonal deletion of mature T lymphocytes. Int Immunol 6:983–989, 1994
McCormack JE, Kappler J, Marrack P: Stimulation with specific antigen can block superantigen-mediated deletion of T cells in vivo. Proc Natl Acad Sci USA 91:2086–2090, 1994
Jupin C, Anderson S, Damais C, Alouf JE, Parant M: Toxic shock syndrome toxin as an inducer of human tumor necrosis factors and γ-interferon. J Exp Med 167:752–761, 1988
Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H: T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: Critical role of tumor necrosis factor. J Exp Med 175:91–98, 1992
Hackett SP, Stevens DL: Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-beta synthesis. J Infect Dis 168:232–235, 1993
Miethke T, Wahl C, Regele D, Gaus H, Heeg K, Wagner H: Superantigen mediated shock: A cytokine release syndrome. Immunobiology 189:270–284, 1993
Bradley GS, Campbell YG, Castle RM, Grove SA: Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1. Infect Immun 67:1521–1525, 1999
Bette M, Schafer MK-H, van Rooijen N, Weihe E. Fleischer B: Distribution and kinetics of superantigen-induced cytokine gene expression in mouse spleen J Exp Med 1993; 178:1531–1540.
Marrack P, Blackman M, Kushnir E, Kappler J: The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med 171:455–464, 1990
Miethke T, Duschek K, Wahl C, Heeg K, Wagner H: Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol 23:1494–1500, 1993
Trede NS, Geha RS, Chatila T: Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands. J Immunol 146:2310–2315, 1991
Abe J, Takeda T: Characterization of a superantigen produced by Yersinia Pseudotuberculosis. In Superantigens: Molecular Biology, Immunology, and Relevance to Human Disease, DYM Leung, BT Huber, PM Schlievert (eds). New York, Marcel Dekker, 1997, p 369
Leung DYM, Schlievert PM: Superantigens in human disease: Future directions in therapy and illucidation of disease pathogenesis. In Superantigens, DYM Leung, BT Huber, PM Schlievert (eds). New York, Marcel Dekker, 1997, p 581
Bonventre PF, Heeg H, Cullen C, Lian CJ: Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun 61:793–799, 1993
de Azavedo JC, Foster TJ, Hartigan PJ, et al.: Expression of the cloned toxic shock syndrome toxin 1 gene (tst) in vivo with a rabbit uterine model. Infect Immun 50:304–309, 1985
Tracey KJ, Beutler B, Lowry SF, et al.: Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474, 1986
Miethke T, Wahl C, Wagner H: Role of cytokines/lymphokines in Gram-positive bacterial infections. In Human Cytokines: Their Role in Disease and Therapy, BB Aggarwal, RK Puri (eds). Cambridge, MA, Blackwell Science, 1995, p 371
Chapman PB, Lester TJ, Casper ES, et al.: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5:1942–1951, 1987
Pfeffer K, Matsuyama T, Kundig TM, et al.: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457–467, 1993
Zembowicz A, Vane JR: Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line. Proc Natl Acad Sci USA 89:2051–2055, 1992
MacMicking JD, Nathan C, Hom G, et al: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase published erratum appears in Cell 1995 Jun 30;81(17): following 1170]. Cell 81:641–650, 1995
Beutler B, Cerami A: The biology of cachectin/TNF—A primary mediator of the host response. Annu Rev Immunol 7:625–655, 1989
Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162–1172, 1988
Montegut W, Lowry SF, Moldawer LL: Role of cytokines in septic shock and shock-related syndromes. In Human Cytokines: Their Role in Disease and Therapy, BB Aggarwal, RK Puri (eds). Cambridge, MA, Blackwell Science, 1995, p 381
Smith JW, Urba WJ, Curti BD, et al.: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 10:1141–1152, 1992
Beutler B, Beutler S: The pathogenesis of fever. In Cecil Textbook of Medicine, JB Wyngaarden, LH Smith, JC Bennet (eds). Philadelphia, W. B. Saunders, 1992, p 1568
Brysk MM, Bell T, Hoida C, Tyring SK, Rajaraman S: Interferon-gamma modulates terminal differentiation and the expression of desquamin in cultured keratinocytes. Exp Cell Res 197:140–147, 1991
Brysk MM, Bell T, Brysk H, Selvanayagam P, Rajaraman S: Enzymatic activity of desquamin. Exp Cell Res 214:22–26, 1994
Rosenberg SA, Lotze MT, Muul LM, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897, 1987
Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337–342, 1985
Stevens DL: The toxic shock syndromes. Infect Dis Clin North Am 10:727–746, 1996
Dohlsten M, Hedlund G, Segren S, et al.: Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: Evidence for a novel enterotoxin receptor. Eur J Immunol 21:1229–1233, 1991
Alber G, Hammer DK, Fleischer B: Relationship between enterotoxic-and T lymphocyte-stimulating activity of staphylococcal enterotoxin B. J Immunol 144:4501–4506, 1990
Reck B, Scheuber PH, Londong W, Sailer-Kramer B, Bartsch K, Hammer DK: Protection against the staphylococcal enterotoxin-induced intestinal disorder in the monkey by anti-idiotypic antibodies. Proc Natl Acad Sci USA 85:3170–3174, 1988
Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ: Lack of complete correlation between emetic and T-cell-stimulatory activities of staphylococcal enterotoxins. Infect Immun 61:3175–3183, 1993
Rogers TJ, Guan L, Zhang L: Characterization of an alternative superantigen binding site expressed on a renal fibroblast cell line. Int Immunol 7:1721–1727, 1995
Hamad ARA, Marrack P, Kappler JW: Transcytosis of staphylococcal superantigen toxins. J Exp Med 185:1447–1454, 1997
Lionetti P, Spencer J, Breese EJ, Murch SH, Taylor J, MacDonald TT: Activation of mucosal V beta 3+ T cells and tissue damage in human small intestine by the bacterial superantigen, Staphylococcus aureus enterotoxin B. Eur J Immunol 23:664–668, 1993
Spiekermann GM, Nagler-Anderson C: Oral administration of the bacterial superantigen staphylococcal enterotoxin B induces activation and cytokine production by T cells in murine gut-associated lymphoid tissue. J Immunol 161:5825–5831, 1998
McKay DM, Benjamin MA, Lu J: CD4+ T cells mediate superantigen-induced abnormalities in murine jejunal ion transport. Am J Physiol 275:G29-G38, 1998
McKay DM, Singh PK: Superantigen activation of immune cells evokes epithelial (T84) transport and barrier abnormalities via IFN-gamma and TNF alpha: Inhibition of increased permeability, but not diminished secretory responses by TGF-beta2. J Immunol 159:2382–2390, 1997
Chapman PB, Kolitz JE, Hakes TB, et al.: A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Invest New Drugs 6:179–188, 1988
Ohmen JD, Barnes PF, Grisso CL, Bloom BR, Modlin RL: Evidence for a superantigen in human tuberculosis. Immunity 1:35–43, 1994
Cohen-Tervaert JW, Popa ER, Bos NA: The role of superantigens in vasculitis. Curr Opin Rheumatol 11:24–33, 1999
Leung DY, Travers JB, Giorno R, et al.: Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 96:2106–2112, 1995
Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? [see comments]. Immunol Today 16:145–149, 1995
Dobrescu D, Ursea B, Pope M, Asch AS, Posnett DN: Enhanced HIV-1 replication in Vb12 T cells due to human cytomegalovirus in monocytes: Evidence for a putative herpesvirus superantigen. Cell 82:753–763, 1995
Sutkowski N, Palkama T, Ciurli C, Sekaly R-P, Thorley-Lawson DA, Huber BT: An Epstein-Barr virus associated superantigen. J Exp Med 184:971–980, 1996
Posnett DN: Viral superantigens in humans. A potential role in HIV and CMV infection. In Superantigens: Structure, Biology and Relevance to Human Disease, DYM Leung, B Huber, P Schlievert (eds). New York, Marcel Dekker, 1997, p 503
Lafon M: Superantigen in rabies virus and its involvement in paralysis. In Superantigens, DYM Leung, B Huber, P Schlievert (eds). New York, Marcel Dekker, 1997, p 85
Tsiagbe VK, Asakawa J, Miranda A, Sutherland RM, Paterson Y, Thorbecke GJ: Syngeneic response to SJL follicular center B cell lymphoma (reticular cell sarcoma) cells is primarily in V beta 16+ CD4+ T cells. J Immunol 150:5519–5528, 1993
Tsiagbe VK, Yoshimoto T, Asakawa J, Cho SY, Meruelo D, Thorbecke GJ: Linkage of superantigen-like stimulation of syngeneic T cells in a mouse model of follicular center B cell lymphoma to transcription of endogenous mammary tumor virus. EMBO J 12:2313–2320, 1993
Monday SR, Vath GM, Witold AF, et al.: Unique superantigen activity of staphylococcal exfoliative toxins. J Immunolo 162:4550–4559, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernal, A., Proft, T., Fraser, J.D. et al. Superantigens in Human Disease. J Clin Immunol 19, 149–157 (1999). https://doi.org/10.1023/A:1020547509410
Issue Date:
DOI: https://doi.org/10.1023/A:1020547509410